GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Allergan Plc (AGN) [hlAlert]

Rating:
Buy ACT
up 616.58 %

Actavis Inc. (ACT) rated Buy with price target $310 by Argus

Posted on: Friday,  Nov 21, 2014  9:25 AM ET by Argus

Argus rated Buy Allergan Plc (NYSE: AGN) on 11/21/2014. Previously Argus rated Buy Allergan Plc (NYSE: AGN) on 10/04/2010., when
the stock price was $43.54. Since then, Allergan Plc has gained 616.58% as of 11/24/2015's recent price of $312.00.
If you would have followed the previous Argus's recommendation on AGN, you would have gained 616.58% of your investment in 1877 days.

Watson Pharmaceuticals, Inc. (Watson) is a specialty pharmaceutical company engaged in the development, manufacture, marketing, sale and distribution of brand and generic (off-patent) pharmaceutical products. Watson operates and manages its business as three operating segments: Generic, Brand and Distribution. As of December 31, 2008, the Company marketed approximately 150 generic pharmaceutical product families and 27 brand pharmaceutical product families through its generic and brand divisions, respectively, and distributed approximately 8,000 stock-keeping units (SKUs) through its distribution division. The Company?s operations are based predominantly in the United States and India, with its key commercial market being the United States. In July 2008, Watson and Mylan Inc. announced that Mylan Inc. has acquired Watson?s 50% interest in the Somerset Pharmaceuticals, Inc. joint venture. In December 2009, the Company completed the acquisition of Arrow Group.

Argus Research is an independent research firm, and our business is producing, distributing and marketing high-quality investment and economic research. Our recommendations - BUY, HOLD and SELL - reflect the judgment of an analyst about a company's prospects as an investment in terms of value, expected growth and risks. Argus Research does not bring companies public, advise companies on mergers and acquisitions, broker trades, make markets in stocks or manage money. Our independence allows us to make critical judgments about companies that we might not be so free to make were we competing for a firm's underwriting business. Because we're not a broker/dealer, we don't have "inventory" of a stock that we have to move with a tainted recommendation. We have developed a six-point system for analyzing the stocks in our Universe of Coverage. We believe that this system
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/20/2015 8:25 AM Buy
None
289.80 340.00
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/21/2014 9:25 AM Buy
None
261.91 310.00
1/17/2014 3:25 PM Buy
None
183.81 198.00
7/30/2013 9:25 AM Buy
None
135.56 150.00
7/12/2011 9:25 AM Buy
None
69.22 78.00
10/4/2010 8:25 AM Buy
None
43.54 51.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy